Docetaxel resistance in prostate cancer: Taking it up a notch

Tian Zhang, Andrew J. Armstrong

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)4505-4507
Number of pages3
JournalClinical Cancer Research
Issue number20
StatePublished - Oct 15 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Docetaxel resistance in prostate cancer: Taking it up a notch'. Together they form a unique fingerprint.

Cite this